CTLA4 and cancer: The large-scale application of immune checkpoint inhibitor (ICI) therapy, such as anti-programmed death 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has greatly improved the survival rate of cancer patients (1–7).